Axon Enterprise, Inc $AXON Shares Bought by Whitaker Myers Wealth Managers LTD.

Key Points

• Whitaker Myers Wealth Managers LTD. increased its position in Axon Enterprise by 76.5% during Q2, acquiring an additional 796 shares and holding a total of 1,837 shares worth approximately $1.52 million.
• Several institutional investors, including Vanguard Group and Alliancebernstein, have also increased their stakes in Axon Enterprise, with 79.08% of the company's stock now held by institutions.
• Axon Enterprise recently beat analyst estimates with an EPS of $2.12 for the latest quarter, alongside revenue of $668.54 million, marking a year-over-year increase of 32.6%.

Whitaker Myers Wealth Managers LTD. increased its position in Axon Enterprise, Inc (NASDAQ:AXON - Free Report) by 76.5% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,837 shares of the biotechnology company's stock after acquiring an additional 796 shares during the period. Axon Enterprise makes up about 0.4% of Whitaker Myers Wealth Managers LTD.'s investment portfolio, making the stock its 28th biggest position. Whitaker Myers Wealth Managers LTD.'s holdings in Axon Enterprise were worth $1,521,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Axon Enterprise by 2.2% in the 1st quarter. Vanguard Group Inc. now owns 8,632,008 shares of the biotechnology company's stock worth $4,540,005,000 after acquiring an additional 185,571 shares during the period. Alliancebernstein L.P. grew its holdings in shares of Axon Enterprise by 15.9% in the 1st quarter. Alliancebernstein L.P. now owns 1,284,935 shares of the biotechnology company's stock worth $675,812,000 after acquiring an additional 175,890 shares during the period. Westfield Capital Management Co. LP grew its holdings in shares of Axon Enterprise by 29.8% in the 1st quarter. Westfield Capital Management Co. LP now owns 927,801 shares of the biotechnology company's stock worth $487,977,000 after acquiring an additional 212,931 shares during the period. GAMMA Investing LLC grew its holdings in shares of Axon Enterprise by 58,725.5% in the 1st quarter. GAMMA Investing LLC now owns 764,731 shares of the biotechnology company's stock worth $402,210,000 after acquiring an additional 763,431 shares during the period. Finally, Northern Trust Corp grew its holdings in shares of Axon Enterprise by 1.2% in the 1st quarter. Northern Trust Corp now owns 725,720 shares of the biotechnology company's stock worth $381,692,000 after acquiring an additional 8,794 shares during the period. Institutional investors and hedge funds own 79.08% of the company's stock.

Insider Activity at Axon Enterprise

In other Axon Enterprise news, President Joshua Isner sold 15,919 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $746.26, for a total transaction of $11,879,712.94. Following the transaction, the president owned 238,379 shares of the company's stock, valued at $177,892,712.54. This represents a 6.26% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, insider Jeffrey C. Kunins sold 7,891 shares of the stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $750.10, for a total value of $5,919,039.10. Following the transaction, the insider directly owned 144,538 shares in the company, valued at approximately $108,417,953.80. This represents a 5.18% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 44,790 shares of company stock worth $34,304,947. Company insiders own 4.40% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on AXON shares. Northland Securities set a $800.00 price target on Axon Enterprise in a report on Tuesday, August 5th. JPMorgan Chase & Co. upped their price target on Axon Enterprise from $730.00 to $850.00 and gave the stock an "overweight" rating in a report on Thursday, July 17th. Zacks Research cut Axon Enterprise from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 2nd. Bank of America increased their target price on Axon Enterprise from $895.00 to $1,000.00 and gave the company a "buy" rating in a report on Wednesday, August 6th. Finally, UBS Group reiterated a "neutral" rating and set a $840.00 target price (up previously from $820.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Thirteen analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $837.69.

Axon Enterprise Price Performance

Shares of NASDAQ:AXON opened at $756.13 on Friday. The business's fifty day moving average price is $761.10 and its two-hundred day moving average price is $687.25. The stock has a market cap of $59.36 billion, a PE ratio of 186.70, a price-to-earnings-growth ratio of 27.57 and a beta of 1.40. The company has a debt-to-equity ratio of 0.63, a quick ratio of 2.71 and a current ratio of 2.95. Axon Enterprise, Inc has a one year low of $375.71 and a one year high of $885.91.

Axon Enterprise (NASDAQ:AXON - Get Free Report) last announced its earnings results on Monday, August 4th. The biotechnology company reported $2.12 EPS for the quarter, beating analysts' consensus estimates of $1.54 by $0.58. The firm had revenue of $668.54 million for the quarter, compared to analysts' expectations of $641.77 million. Axon Enterprise had a return on equity of 6.80% and a net margin of 13.64%.Axon Enterprise's quarterly revenue was up 32.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.20 EPS. Axon Enterprise has set its FY 2025 guidance at EPS. On average, analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current fiscal year.

Axon Enterprise Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.